Finance entity

James Head

Person

Every one of those 1 sits in a single category, markets. James Head is most often covered alongside Alignment Healthcare, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window.

Last mentioned: Mar 14, 2026

Entity pulse

Recent coverage · James Head

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about James Head

Every one of those 1 sits in a single category, markets. James Head is most often covered alongside Alignment Healthcare, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.4 for that window. James Head appears in 1 tracked Finance story from March 14, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering James Head. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Insider Selling

    President and another insider sell a combined 33,157 shares.

  2. Analyst Downgrade

    Wall Street Zen cuts ALHC rating to Hold.

  3. Secondary Offering

    Company prices 13.2M shares at $19.46 to raise capital.

  4. Q4 Earnings Report

    Alignment Healthcare reports declining losses and operational growth.

Stories mentioning James Head 1

Markets Neutral

Alignment Healthcare Insider Sales Follow $257M Secondary Offering

Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'

2 sources

James Head is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.